Evaluation of the efficacy of a commercial inactivated genogroup 2b-based porcine epidemic diarrhea virus (PEDV) vaccine and experimental live genogroup 1b exposure against 2b challenge

Table 1 Experimental groups, treatments at different days post PEDV vaccination (dpv), average daily gain (ADG) in grams from dpv 0 to 42 (corresponds to day post challenge 14), length and area under the curve (AUC) of PEDV RNA shedding in feces

Group designation	Number of pigs	Exposure or vaccination					Challenge	ADG^d	Viral shedding in feces^d
Group designation	Number of pigs	Type	Adjuvant	Genogroup	Route	Timing	dpv 28	dpv 0–42	Length (days)	AUC
EXP-IM-1b	7	Experimental live virus	Adjuplex™	G1b	Intramuscularly	dpv 0	PEDV G2b	412.8 ± 29.8^A	10.7 ± 1.5^A,e	236.6^A
EXP-ORAL-1b	8	Experimental live virus	None	G1b	Orally	dpv 0	PEDV G2b	385.2 ± 27.0^A	5.8 ± 0.3^A,B	141.9^A
VAC-IM-2b	8	Commercial inactivated^c	Amphigen^®	G2b	Intramuscularly	dpv 0 and 14	PEDV G2b	402.8 ± 26.1^A	2.5 ± 1.6^B,C	43.9^B
POS-CONTROL^a	8	Saline	None	NA	Intramuscularly	dpv 0	PEDV G2b	379.8 ± 19.5^A	7.5 ± 1.3^A	169.0^A
NEG-CONTROL^b	8	Saline	None	NA	Orally	dpv 0	Saline	460.0 ± 22.1^A	0.0 ± 0.0^C	0.0^B

^aThe POS-CONTROL group was sham-vaccinated intramuscularly and inoculated with PEDV G2b and served as an unvaccinated, PEDV challenged group.
^bThe NEG-CONTROL group was sham-vaccinated orally with saline and sham-inoculated with saline and served as unvaccinated and unchallenged control group.
^cPorcine Epidemic Diarrhea Vaccine; Zoetis.
^dData presented as group mean ± SEM.
^eDifferent superscripts^(A,B,C) within a column indicate significant (P < 0.05) different group means.

ISSN: 1297-9716